The purpose of this research study is to try and teach a computer program to assess how a dialysis vascular access fistula is maturing, when it could be ready to put needles in, or when it needs to be fixed to allow it to mature better; based on the electronic stethoscope recordings.

Infections occurring in individuals with glomerular disease are preventable contributors to excess healthcare utilization, morbidity, and mortality, and are the leading cause of death in children with glomerular disease. Vaccination is a powerful and cost-effective method to attenuate infectious burden, and clinical guidelines recommend that patients with glomerular disease receive 23-valent pneumococcal (PPSV23) vaccine. The main objective of the study is to determine functional PPSV23 immunogenicity in a prospectively collected multicenter cohort of children with idiopathic nephrotic syndrome using measurements of anti-pneumococcal and opsonophagocytic antibody titers prior to, and 1, 3 and 12 months following PPSV23 vaccination.

This study is comparing two approaches for monitoring and addressing symptoms among adult patients with kidney failure who are treated with hemodialysis. For the first approach patients use an electronic system twice a month to report their symptoms. The system sends alerts to their medical team at the dialysis clinic about the reported symptoms and gives suggestions about how to manage them. The system also provides reports that show patients and their medical team the reported symptoms over time. For the second approach patients complete a quality of life questionnaire that includes questions about symptoms once a year. The questionnaire does not have follow-up support like alerts, symptom management guidance, or reports. In addition, researchers will talk to patients, dialysis clinic personnel, and medical providers about their experiences using the electronic symptom monitoring system to learn about how to best use patient-reported outcome measures in dialysis care.

Belatacept is a drug that helps kidney transplant recipients by preventing the body from rejecting the new organ. We want to compare how well belatacept works compared to the commonly used drug tacrolimus. To do this, we plan to study people who got kidney transplants in the United States from 2011 to 2020. By using two large databases, the United States Renal Data System, and the Scientific Registry of Transplant Recipients, we aim to understand how belatacept is used in real life. We are also interested in comparing how effective and safe is belatacept compared with tacrolimus after one year of administration. We will look at outcomes like how long the transplanted kidney will work, how long will the kidney transplant recipients live, how well your kidneys will work, the risk of organ rejection, and certain side effects to happen after transplant like blood cancer.

The purpose of this study is to compare clinical outcomes and health-related quality of life between an individualized hemodialysis prescription and conventional hemodialysis prescription in individuals requiring chronic hemodialysis who still have residual kidney function.

Liver injury due to prescription and non-prescription medication is medical, scientific, and public health problem of increasing frequency and importance in United States. Drug-induced liver injury (DILI) is the most common reason the Food and Drug Administration (FDA) would choose not to approve a new drug or withdraw a drug from the market. However, drug-induced liver injuries are often under-reported and difficult to detect/diagnose. This study seeks to learn more about these drug-induced liver injuries and develop better ways to detect, define, and study drug-induced liver injuries. The study will be looking at new cases of drug-induced liver injury, as well as gathering data on previous drug-induced liver injury (up to January 1, 1994).

This study will compare 3 different ways to educate patients with advanced chronic kidney disease about hemodialysis vascular access.

A multicenter prospective trial with randomized and observational cohorts assessing patient-reported outcomes and unplanned healthcare utilization following ureteroscopic treatment of renal and ureteral stones, with stent omission versus placement of a ureteral stent.

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).